Trial Profile

A Phase 1 clinical study of HexaPro/HD-MAP COVID-19 vaccine

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HexaPro (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Vaxxas

Most Recent Events

05 Jun 2023 According to a Vaxxas Media Release, Interim study results will be presented at the 2023 BIO International Convention.
05 Jun 2023 Inteirm results presented in a Vaxxas Media Release.
08 Nov 2022 According to a Vaxxas media release, this trial is being conducted in Australia at the University of the Sunshine Coast Sippy Downs clinical research location.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com